Trials / Completed
CompletedNCT01196312
Anxiety Sensitivity Treatment for Heroin Users
Novel Intervention for Drug Use and HIV Risk Among Anxiety Sensitive Heroin Users
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- University of Maryland, College Park · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Anxiety Sensitivity Treatment for Heroin Users is a development project targeting mild and above levels of anxiety sensitivity that will involve the testing of a specialized protocol for improving treatment retention and outcomes for heroin dependent individuals in a residential substance use treatment. ASTH-HR will integrate established treatment modules such as Healthy Relationships, along with interoceptive exposure, affect management, and psycho-education exercises developed for anxiety prevention and treatment programs with standard substance use treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Anxiety sensitivity therapy | ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises). |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-03-01
- Completion
- 2011-09-01
- First posted
- 2010-09-08
- Last updated
- 2023-05-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01196312. Inclusion in this directory is not an endorsement.